Fecal calprotectin measurement as a biomarker of severe disease phenotype in celiac disease and non-celiac enteropathies.

IF 4 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Digestive and Liver Disease Pub Date : 2024-10-05 DOI:10.1016/j.dld.2024.09.010

Annalisa Schiepatti, Alessandro Cappellini, Stiliano Maimaris, Paolo Minerba, Martina Retrosi, Giulia Mantica, Chiara Scarcella, Claudia Delogu, Giovanni Arpa, Paola Ilaria Bianchi, Antonio Di Sabatino, Federico Biagi

{"title":"Fecal calprotectin measurement as a biomarker of severe disease phenotype in celiac disease and non-celiac enteropathies.","authors":"Annalisa Schiepatti, Alessandro Cappellini, Stiliano Maimaris, Paolo Minerba, Martina Retrosi, Giulia Mantica, Chiara Scarcella, Claudia Delogu, Giovanni Arpa, Paola Ilaria Bianchi, Antonio Di Sabatino, Federico Biagi","doi":"10.1016/j.dld.2024.09.010","DOIUrl":null,"url":null,"abstract":"Background: Fecal calprotectin (FC) is a non-invasive biomarker of gut inflammation, but its role in celiac disease (CD) and non-celiac enteropathies (NCEs) is undefined.Aims: To retrospectively evaluate FC in patients with CD and NCEs as a tool for assessing disease activity and predicting long-term outcomes.Methods: Patients with uncomplicated and complicated CD, and NCEs with data on FC, evaluated at our center between June-2008 and December-2023, were enrolled. The relationship between elevated FC (>50 mg/kg) and disease activity was statistically analysed and Cox regression adjusted for age and sex was used to compare development of complications and mortality in patients with elevated and normal FC.Results: 177 patients (109F, mean age at diagnosis 39±20 years, 132 CD, 17 complicated CD, 28 NCEs) were enrolled. 55 patients had elevated FC, which was associated with lack of clinical and histological response to therapy (both p < 0.001). During a median follow-up of 103 months (IQR 54-176), 22 patients developed complications (15.4 %) and 21 died (11.9 %). Elevated FC was significantly more common in complicated CD (70.6 %) and NCEs (67.9 %) than in uncomplicated CD (18.2 %), p < 0.001. Elevated FC was independently predictive of developing complications (HR 4.8,95 %CI 1.4-17.7, p = 0.01) and mortality (HR 4.8,95 %CI 1.6-14.3, p < 0.01).Conclusion: FC is a promising non-invasive biomarker for assessing disease severity and long-term outcomes in CD and NCEs.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive and Liver Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.dld.2024.09.010","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Fecal calprotectin (FC) is a non-invasive biomarker of gut inflammation, but its role in celiac disease (CD) and non-celiac enteropathies (NCEs) is undefined.

Aims: To retrospectively evaluate FC in patients with CD and NCEs as a tool for assessing disease activity and predicting long-term outcomes.

Methods: Patients with uncomplicated and complicated CD, and NCEs with data on FC, evaluated at our center between June-2008 and December-2023, were enrolled. The relationship between elevated FC (>50 mg/kg) and disease activity was statistically analysed and Cox regression adjusted for age and sex was used to compare development of complications and mortality in patients with elevated and normal FC.

Results: 177 patients (109F, mean age at diagnosis 39±20 years, 132 CD, 17 complicated CD, 28 NCEs) were enrolled. 55 patients had elevated FC, which was associated with lack of clinical and histological response to therapy (both p < 0.001). During a median follow-up of 103 months (IQR 54-176), 22 patients developed complications (15.4 %) and 21 died (11.9 %). Elevated FC was significantly more common in complicated CD (70.6 %) and NCEs (67.9 %) than in uncomplicated CD (18.2 %), p < 0.001. Elevated FC was independently predictive of developing complications (HR 4.8,95 %CI 1.4-17.7, p = 0.01) and mortality (HR 4.8,95 %CI 1.6-14.3, p < 0.01).

Conclusion: FC is a promising non-invasive biomarker for assessing disease severity and long-term outcomes in CD and NCEs.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

粪便钙蛋白检测作为乳糜泻和非乳糜泻性肠病严重疾病表型的生物标志物。

背景：目的：回顾性评估 CD 和 NCE 患者的 FC，作为评估疾病活动性和预测长期预后的工具：方法：纳入2008年6月至2023年12月期间在本中心接受评估的无并发症和并发症CD患者以及有FC数据的NCE患者。统计分析了FC升高（>50 mg/kg）与疾病活动性之间的关系，并使用调整了年龄和性别的Cox回归比较了FC升高和正常患者的并发症发生率和死亡率：共纳入177名患者（109F，诊断时平均年龄（39±20）岁，132名CD患者，17名复杂CD患者，28名NCE患者）。55名患者的FC升高，这与临床和组织学治疗缺乏反应有关（P均<0.001）。在中位随访 103 个月（IQR 54-176）期间，22 名患者出现并发症（15.4%），21 名患者死亡（11.9%）。在复杂性 CD（70.6%）和 NCEs（67.9%）患者中，FC 升高的比例明显高于非复杂性 CD（18.2%），P < 0.001。FC升高可独立预测并发症（HR 4.8，95 %CI 1.4-17.7，p = 0.01）和死亡率（HR 4.8，95 %CI 1.6-14.3，p < 0.01）：FC是一种很有前景的非侵入性生物标记物，可用于评估CD和NCE的疾病严重程度和长期预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Digestive and Liver Disease 医学-胃肠肝病学

CiteScore

6.10

自引率

2.20%

发文量

632

审稿时长

19 days

期刊介绍： Digestive and Liver Disease is an international journal of Gastroenterology and Hepatology. It is the official journal of Italian Association for the Study of the Liver (AISF); Italian Association for the Study of the Pancreas (AISP); Italian Association for Digestive Endoscopy (SIED); Italian Association for Hospital Gastroenterologists and Digestive Endoscopists (AIGO); Italian Society of Gastroenterology (SIGE); Italian Society of Pediatric Gastroenterology and Hepatology (SIGENP) and Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease publishes papers on basic and clinical research in the field of gastroenterology and hepatology. Contributions consist of: Original Papers Correspondence to the Editor Editorials, Reviews and Special Articles Progress Reports Image of the Month Congress Proceedings Symposia and Mini-symposia.